etoposide has been researched along with olaparib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM | 1 |
| Kondo, T; Miyamoto, M; Ohta, T; Watanabe, T; Yamamoto, Y; Yamasaki, H | 1 |
| de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
| Baker, K; Blackhall, F; Dive, C; Forster, M; Foy, V; Frese, KK; Gomes, F; Lallo, A; Schenk, MW | 1 |
| Karapetian, M; Kulikova, N; Kurdadze, A; Tsikarishvili, S; Zaalishvili, G | 1 |
| Clarke, PA; Fay, M; Lovato, T; Marlow, M; McCrorie, P; Mistry, J; Rahman, R; Ritchie, AA; Smith, SJ; Taresco, V; Ward, I | 1 |
| Chu, WK; Jiang, Y; Yam, JC | 1 |
| Byers, L; Califano, R; Chafin, W; Cho, BC; Faivre-Finn, C; Jabbour, SK; Kato, T; Lai, WV; Rimner, A; Rudin, CM; Yu, J; Yu, L; Zhao, B | 1 |
1 review(s) available for etoposide and olaparib
| Article | Year |
|---|---|
Targeting DNA damage in SCLC.
Topics: Aurora Kinases; Azepines; Benzimidazoles; Carbolines; Cell Cycle Checkpoints; Cell Proliferation; Cytotoxins; DNA Damage; DNA Repair; Etoposide; Genomic Instability; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Rad51 Recombinase; Small Cell Lung Carcinoma | 2017 |
1 trial(s) available for etoposide and olaparib
| Article | Year |
|---|---|
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Etoposide; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2022 |
6 other study(ies) available for etoposide and olaparib
| Article | Year |
|---|---|
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomycin; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Ifosfamide; Metabolic Networks and Pathways; Mitochondria; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Temozolomide; Vincristine | 2015 |
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Topics: Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; Etoposide; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation, Ionizing; Recombinational DNA Repair; Sarcoma, Synovial; Temozolomide; Topoisomerase II Inhibitors | 2016 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
Topics: Animals; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Embryonic Development; Etoposide; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Zebrafish | 2020 |
Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours.
Topics: Adhesiveness; Aerosols; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Drug Carriers; Drug Compounding; Drug Liberation; Etoposide; Glioblastoma; Humans; Hydrogels; Lactates; Male; Mice, Nude; Nanoparticles; Pectins; Phthalazines; Piperazines; Polyethylene Glycols; Rats; Solubility; Tissue Distribution | 2020 |
Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Dose-Response Relationship, Drug; Etoposide; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair; Retinoblastoma; Retinoblastoma Protein | 2021 |